Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza™) in diabetic neuropathic pain patients: detection of distinct response groups by Martini, Christian et al.
© 2012 Martini et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Pain Research 2012:5 51–59
Journal of Pain Research
Pharmacodynamic analysis of the analgesic effect 
of capsaicin 8% patch (QutenzaTM) in diabetic 
neuropathic pain patients: detection of distinct 
response groups
Christian Martini1,*
Ashraf Yassen2,*
Erik Olofsen1
Paul Passier2
Malcom Stoker3
Albert Dahan1
1Department of Anesthesiology, 
Leiden University Medical Center, 
Leiden, The Netherlands; 2Global 
Clinical Pharmacology and 
Exploratory Development, Astellas 
Pharma Global Development Europe, 
Leiderdorp, The Netherlands; 
3Global Medical Sciences, Astellas 
Pharma Global Development Europe, 
Leiderdorp, The Netherlands
*These authors contributed equally  
to this work
Correspondence: Albert Dahan 
Department of Anesthesiology,  
Leiden University Medical Center,  
P5-Q, 2300 RC Leiden, The Netherlands 
Tel +31 71 526 2301 
Fax +31 71 526 6230 
Email a.dahan@lumc.nl
Abstract: Treatment of chronic pain is associated with high variability in the response to phar-
macological interventions. A mathematical pharmacodynamic model was developed to quantify 
the magnitude and onset/offset times of effect of a single capsaicin 8% patch application in the 
treatment of painful diabetic peripheral neuropathy in 91 patients. In addition, a mixture model 
was applied to objectively match patterns in pain-associated behavior. The model identified 
four distinct subgroups that responded differently to treatment: 3.3% of patients (subgroup 1) 
showed worsening of pain; 31% (subgroup 2) showed no change; 32% (subgroup 3) showed 
a quick reduction in pain that reached a nadir in week 3, followed by a slow return towards 
baseline (16% ± 6% pain reduction in week 12); 34% (subgroup 4) showed a quick reduction 
in pain that persisted (70% ± 5% reduction in week 12). The estimate of the response-onset rate 
constant, obtained for subgroups 1, 3, and 4, was 0.76 ± 0.12 week−1 (median ± SE), indicating 
that every 0.91 weeks the pain score reduces or increases by 50% relative to the score of the 
previous week (= t½). The response-offset rate constant could be determined for subgroup 3 
only and was 0.09 ± 0.04 week−1 (t½ 7.8 weeks). The analysis allowed separation of a hetero-
geneous neuropathic pain population into four homogenous subgroups with distinct behaviors 
in response to treatment with capsaicin. It is argued that this model-based approach may have 
added value in analyzing longitudinal chronic pain data and allows optimization of treatment 
algorithms for patients suffering from chronic pain conditions.
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Introduction
The development of painful diabetic peripheral neuropathy (DPN) is a common long-
term complication in diabetic patients. It is relatively more common in older patients 
and patients with suboptimal glycemic control.1 Although the exact pathophysiologic 
mechanism is unknown, several contributing factors have been proposed, such as 
microvascular insufficiency, oxidative stress, nitrosative stress, defective neurotro-
phism, and autoimmune-mediated nerve destruction.2,3 Patients with DPN exhibit a 
variety of pain symptoms and sensory qualities. Approximately 20%–24% of patients 
experience onset of insidious pain (or dysesthesias) and present with varying degrees 
of numbness, tingling, burning pain, loss of sensations, paresthesias and loss of balance 
or coordination. Of the 60% of diabetics who develop neuropathy, about 30%–40% 
have no symptoms.4
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Attempts to treat DPN can be divided into those directed 
at modification of the underlying disease process and those 
directed toward symptom suppression.5 No consensus on 
the optimal management of neuropathic pain exists and 
consequently the treatment of pain is largely empirical and 
diverse, relying primarily on antidepressants, anticonvulsants 
and narcotic analgesics.6 This study focuses on the local 
application of a high concentration (8%) capsaicin patch, 
NGX-4010 (QutenzaTM) for treatment of painful DPN. 
Capsaicin is the pungent ingredient in chili peppers and it 
is believed that exaggerated activity of capsaicin-sensitive 
nerve fibers is involved in the pain of peripheral neuropathies 
like DPN and postherpetic neuralgia.7 Capsaicin is a highly 
selective activating ligand for transient receptor potential 
vanilloid 1 (TRPV1), which is a ligand-gated nonselective 
cation channel highly expressed in small diameter primary 
afferent neurons (C- and Aδ-fibers), especially those nerve 
fibers that specialize in the detection of painful or noxious 
sensations,8–10 Activation of this receptor by capsaicin 
results in a burning sensation, hyperalgesia, allodynia, and 
erythema (due to release of vasoactive neuropeptides from 
small-diameter sensory axons).9 After prolonged exposure 
to capsaicin, the small diameter sensory axons become less 
sensitive to a variety of stimuli, including capsaicin itself 
or thermal stimuli, resulting in a reduced pain response.8 
These later stage effects of capsaicin are frequently referred 
to as “defunctionalization” and serve as the rationale for the 
development of capsaicin formulations for the treatment of 
various neuropathic pain syndromes.7 Studies have shown 
that such alterations from prolonged low-concentration cap-
saicin exposure are reversible, at which point normal function 
(the detection of noxious sensations) returns.11,12
In this study, patients received a single treatment with 
the high concentration capsaicin patch (NGX-4010). While a 
(limited) descriptive analysis of the data has been published 
previously,20 an independent re-analysis was performed, 
using nonlinear mixed effect modeling in NONMEM con-
sidering the whole time course of effect (0–12 weeks).14 
The aims of the study were (i) to get an indication of the 
variability in responses and attempt to identify subgroups in 
response to capsaicin treatment using a pharmacodynamic 
mixture model; (ii) to describe the magnitude of effect and 
time courses of onset and offset of effect of 8% capsaicin 
patch in the observed subgroups.
Methods
The study was registered in the Clinical Trial register (www.
clinicaltrials.gov) under number NCT00082316.
Patient population and study design
After approval of the protocol by the local ethics committee 
patients with moderate to severe pain (numerical pain rating 
score [NPRS] of 3 or greater on a scale from 0 [no pain] to 
10 [worst possible pain]), secondary to DPN were enrolled 
in the study. DPN was defined as neuropathic pain (related to 
type I or II diabetes mellitus) in both feet for at least 3 months 
prior to the study.
Inclusion criteria were: men and women aged at least 
18 years, absence of pain from other causes (eg, from 
fibromyalgia, arthritis, mononeuritis multiplex, hereditary 
neuropathy), intact skin around the treatment area, absence 
of significant medical problems of the heart, kidneys, liver, 
or lungs. Chronic pain medication was allowed with the 
exception of any topical medication in the affected areas of 
the body, including nonsteroidal anti-inflammatory drugs, 
menthol, methyl salicylate, local anesthetics, steroids, or 
capsaicin. After the screening visit, no pain medication 
changes were allowed. Exclusion criteria included a history 
of substance abuse, pregnancy or lactation, the presence of 
cancer, opioid medication use, unless orally or transdermally 
administered and not exceeding a total daily dose of mor-
phine 60 mg/day, chronic alcohol abuse, uncorrected vitamin 
B12 deficiency, or treatment with any drugs that may have 
contributed to the neuropathy during the 90 days prior to 
the study, hypersensitivity to capsaicin (ie, chili peppers or 
over-the-counter capsaicin products), local anesthetics or 
adhesives.
This multicenter study had a randomized, open-label 
design and was aimed at the evaluation of the tolerability 
and efficacy of the application of 1–4 high-concentration 
capsaicin (640 µg/cm2) patches, preceded by the topical 
application of lidocaine 4%. Prior to treatment with NGX-
4010, the lidocaine cream was applied over and extending 
1–2 cm beyond the perimeter of the marked painful area(s) 
for 60 minutes. After removal of the topical anesthetic, 
up to four 20 × 14 cm capsaicin patches were applied for 
60–90   minutes. The patch(es) were then removed and a 
cleansing gel was used to remove excess capsaicin from the 
skin, after which the treated area was gently washed with soap 
followed by water. The patients were monitored for at least 
2 hours following treatment before being discharged. For 
discomfort, the patients were permitted to use analgesic medi-
cations during (oxycodone oral solution 1 mg/mL) and after 
treatment (hydrocodone/acetaminophen tablets, 5/500 mg, 
two tablets every 8 hours, for a maximum of 5 days).
The primary study parameter was the average NPRS for 
the past 24 hours obtained at 24 hour intervals at 0900 PM. 
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Average weekly NPRSs were used in the analysis, without 
imputation for missing scores. Pain scores were obtained for 
12 weeks following the application of the capsaicin patch.
Pharmacodynamic data analysis
Model fitting was performed using a nonlinear mixed 
effects modeling approach using nonlinear mixed effect 
modeling software (NONMEM version VII level 1; ICON 
Development Solutions, Ellicott City, MD).14 The first-order 
conditional estimation (FOCE) with interaction algorithm 
was used for model development. The performance of the 
analysis was evaluated by various selection criteria, includ-
ing visual inspection of the goodness-of-fit plot, changes in 
the objective function value and parameter estimates and 
their respective standard errors. Using the likelihood ratio 
test, the significance level was set at α = 0.01, which cor-
responds to a reduction of 6.6 units in objective function 
value (χ2 distribution) to discriminate between two nested 
structural models after inclusion of one additional parameter. 
Model diagnostic checks of the final model were conducted 
using R (R-project, version 2.12.0).
Pharmacodynamic model
The effect of capsaicin 8% on NPRS was characterized using 
a Bateman function with the following structure:
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k
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onset
onset offset
k time k time offset onset =
−
⋅−
−⋅ −⋅ ()   (1)
The Bateman function characterizes the time course of 
NPRS pain score from week 0 (baseline) to week 12 in terms 
of two first-order rate constants describing the onset (konset) 
and offset (koffset) of the effect following the application of 
capsaicin 8%. The change in NPRS from week 0 to week 12 
was computed as follows:
  NPRS(t) = NPRS0 ⋅ (1 − α ⋅ Effect)  (2)
where NPRS0 is the NPRS pain score at baseline and α is 
the magnitude of effect.
Random effects were included in the pharmacodynamic 
model provided that the parameters are either normally or 
log-normally distributed. For example, the pharmacodynamic 
parameter α was modeled assuming a normal distribution 
allowing for the estimation of negative values of the para-
meter α (increase in NPRS pain score):
 α j = θα + ηj  (3)
where αj is the estimate of α for the jth individual and θα 
represents the population estimate for the pharmacodynamic 
parameter α. ηj describes the inter-individual variability on 
α, which is assumed to be a normally distributed random 
effect variable with mean zero and variance ω2. Similarly, 
the inter-individual random effect variables for NPRS0 and 
konset were assumed to be normally distributed. The inter-
individual variability random effect variable for koffset was 
assumed to be log-normally distributed.
Residual variability, which is a measure of the unex-
plained variability (including error associated with reporting 
of chronic pain outcome), was described using an additive 
error model:
  NPRSobs,ij = NPRSpred,ij + εij,  (4)
where the residual variability, εij, at time point i for 
  individual j, is a normally distributed random effect variable 
with mean zero and variance σ2.
Mixture model
Aside from the advantage of the use of the population approach 
in simultaneously analyzing individual data, the nonlinear 
mixed effects modeling approach also enables the definition 
of a mixture model, in which the existence of subgroup of 
patients that may respond differently to capsaicin 8% patch 
treatment can be explored. For this analysis, it is assumed 
that the structural model is the same for subgroups, but that 
patients may differ in their onset and offset of response and 
also may respond differently to capsaicin 8% patch in terms 
of magnitude of response. To this end, the pharmacodynamic 
parameters, konset, koffset and α are assumed to be distributed 
multimodally and therefore the mixture feature in NONMEM 
is used to differentiate between subgroups of patients on the 
basis of the distribution of the pharmacodynamic parameter 
estimates. Initially, based on visual inspection of the individual 
data, the mixture model was defined to separate four sub-
groups of patients, including patients that show (1)   worsening 
of response, (2) no response, (3) maximum response with 
trend to return to baseline after 12 weeks and (4) maximum 
response which is maintained during 12 weeks.
Results
The data from 91 patients were included in the analysis. 
Data of patients with early termination from the study were 
included in the analysis (n = 13). Early termination was 
most often related to unsatisfactory therapeutic response and 
occurred most often in week 6 of the study. An overview 
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of the demographic patient data (of patients included in the 
analysis) is provided in Table 1. The mean time course pro-
files of the numerical pain rating score for the total popula-
tion are shown in Figure 1A. The mean percentage of pain 
reduction from baseline at week 12 for the total population 
was 30.5% (95% confidence interval [CI]: 21.1%–39.9%). 
The proportion of patients that show at least 30% reduction 
in NPRS from baseline at week 12 was 46.8%; the 50% 
responder rate at week 12 was 33.8%.
Description of the four subgroups
The mixture model analysis clearly showed that the dataset 
can be separated into subgroups (Tables 2–4). These sub-
groups have different shapes of the time versus response 
profile, indicating that patients differ in their response to 
capsaicin 8% treatment. The mean time course profiles of 
NPRS pain score for the different subgroups are shown in 
Figure 1B–E. The standard errors shown serve to illustrate 
that the average NPRS score in each subgroup (except for 
subgroup 1) is estimated with a high degree of precision as 
indicated by the relative low standard errors.
Patients in subgroup 1 (n = 3) displayed a worsening of 
response (increase in NPRS score) following capsaicin 8% 
treatment that was maintained during the 12 weeks of the 
study (Figure 1B). The mean increase in NPRS from baseline 
at week 12 was 28.0%. Note, however, that this subgroup 
contains just three subjects.
Subgroup 2 contains 28 patients that showed no or 
minimal response to capsaicin 8% treatment (Figure 1C). On 
average, a slight increase in NPRS pain score from baseline 
of 5.62% was observed (Table 2), while none of the patients 
in that subgroup showed at least 30% reduction in NPRS 
from baseline at week 12.
Subgroup 3 and 4 do show a clear analgesic response 
to capsaicin 8% treatment. On average, the 29 patients in 
subgroup 3 had a quick reduction in NRPS with a nadir 
of 42.6% reduction in NPRS occurring between weeks   
3 and 4, followed by a slow increase NPRS towards baseline 
(Figure 1D). At the end of the study the mean NPRS reduc-
tion was 15.6%, while the proportion of patients that showed 
at least 30% reduction in NPRS pain score was 34.8%; the 
50% responder rate was 13.0%.
Patients in subgroup 4 show a sharp reduction in NPRS 
that was maintained during the 12 weeks of the study 
 ( Figure 1E). The mean percentage reduction in NPRS from 
baseline is 69.7% at week 12% and 90.3% of the patients 
showed at least 30% reduction in NPRS pain score from 
baseline at week 12, while 74.2% of the patients showed at 
least 50% reduction in NPRS pain score from baseline.
To get an indication of the adequacy of the model, 
best, median and worst data fits of NPRS obtained in 
groups 3 and 4 are given in Figure 2. The goodness-of-fit 
plots given in Figure 3 do not show any systemic deviation 
of the model predicted versus observed NPRS.
Pharmacodynamic parameter values
Speed of onset
These distinct profiles are translated into quantitative esti-
mates of pharmacodynamic parameters, which may differ 
across the different subgroups. For subgroups 1, 3, and 4, the 
rate of onset was estimated at 0.76 week–1 (Table 2), corre-
sponding to a half-life (t1/2,onset) of 0.91 weeks, indicating that 
every 0.91 weeks the NPRS is reduced or increased (in case 
of subgroup 1) by 50% relative to the NPRS obtained in the 
previous week. Differences in onset of effect between the sub-
groups has been formally tested for during the analysis, but 
did not result in a further improvement of the model fit at the 
level of α = 0.01, indicating that the rate of onset of response 
is similar for the subgroups. For subgroup 2, the patients that 
showed no or minimal response to capsaicin 8% treatment, 
the rate constant for onset of effect was assumed to be 0 and 
was based on the reasonable assumption that this subgroup 
has no kinetics of action. In total 28 patients of 91 patients 
(30.8%) showed no effect to capsaicin 8% treatment.
Speed of offset
The offset of effect was quite different between the   subgroups. 
Patients in subgroup 3 (n = 29, 31.9%) showed a response 
to capsaicin 8% patch treatment, which gradually returned 
Table 1 Demographics of patients involved in the analysis
Characteristic % of population
Number of patients 91
Sex distribution (n)
  Men 52 (57.1%)
  Women 39 (42.9%)
Age ± SD (years) 58.7 ± 11.21
Age distribution (n)
  ,65 years 63 (69.2%)
  $65 years 28 (30.8%)
  Weight ± SD (kg) 97.7 ± 22.86
  height ± SD (cm) 172.5 ± 9.81
Race distribution (n)
  White 69 (75.8%)
  African American 10 (11.0%)
  hispanic 9 (9.9%)
  Other 3 (3.3%)
Abbreviation: SD, standard deviation.
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toward baseline. The estimate of the rate constant of offset 
for subgroup 3 was 0.09 week–1 (Table 2), corresponding to 
a half-life (t1/2,offset) of 7.8 weeks (based on the 12-week treat-
ment period). This indicates that every 7.8 weeks the NPRS is 
increased by 50% relative to the NPRS of the previous week. 
Subgroups 1, 2 and 4 did not have an offset of effect. For sub-
group 4 (n = 31, 34.1% of patients) this is shown in Figure 1E by 
a well-preserved maintenance of the maximum response during 
the 12 study weeks, showing no offset of effect. For subgroup 1 
(n = 3, 3.3% of patients), NPRS pain scores go up and remain 
at higher scores after treatment with capsaicin 8%.
Discussion
The development of effective and safe treatments for 
chronic neuropathic pain indications remains challenging. 
The heterogeneity (eg, ethnicity, age, sex) and complexity 
(eg, disease processes, underlying mechanisms) of the 
chronic pain population, including DPN patients, is well 
recognized and may partly explain the large variability in 
the response to pharmacological treatment.15,16 In the cur-
rent study a mathematical pharmacodynamic model was 
developed, considering the time course of response, to 
quantify the magnitude and onset/offset times of the effect 
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Figure 1 (A) Mean response of the total population (n = 91). (B) Mean response of patients belonging to group 1 (patients with a deterioration of their pain) as determined 
from the mixture model analysis. (C) Mean response of patients belonging to group 2 (patients with no response to treatment). (D) Mean response of patients belonging 
to group 3 (patients with an initial drop in NPRS followed by a slow decline towards baseline NPRS). (E) Mean response of patients belonging to group 4 (patients with a 
reduction in NRPS which is maintained throughout the study period). Values are mean ± SEM.
Abbreviations: NPRS, numerical pain rating score; SEM, standard error of the mean.
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of capsaicin 8% patch in the treatment of DPN. In addition, 
a mixture model was applied to objectively match patterns   
in pain-associated behavior (NPRS). The main findings of 
the study are: (i) on average, a single application of capsai-
cin 8% patch produced a variable analgesic response with 
an average 30.5% pain reduction (95% CI: 21.1%–39.9%) 
from baseline NPRS at week 12 in DPN patients; and (ii) 
using the pharmacodynamic mixture model, four distinct 
subgroups could be identified that respond differently to 
capsaicin 8% treatment. Subjects allocated to group 1 (3.3% 
of patients) showed worsening of pain; group 2 (31%) showed 
no change in NPRS from baseline pain; group 3 (32%) 
had a quick drop in NPRS with a nadir between weeks 3 
and 4, followed by a slow return towards baseline; group 4 
(34%) had a quick reduction in NPRS that was maintained 
throughout the 12 weeks of the study (Figure 1; Table 2). 
With the exclusion of group 1, each of the groups displayed 
a significant reduction in response variability separating a 
heterogeneous population into homogenous subgroups in 
terms of response to treatment. This further underlines the 
relevance of   collecting time course data during and after the 
treatment period and provides confidence that the developed 
pharmacodynamic model adequately described the time 
course of response in individual patients.
The division into the four subgroups was based on 
characterization of the time course of the response in terms 
of onset/offset times and magnitude of response. The onset 
of response had a half-life of about 1 week that was similar 
for groups 3 and 4 and also group 1. In the latter group 
the response was algesic rather than analgesic. This indi-
cates that the onset of efficacy is relatively fast and within 
3–4 weeks maximum reduction in NPRS was achieved 
(3–4 × t ½onset). Group 1 includes just three patients and 
cannot be considered a robust response group compared to 
groups 2, 3, and 4. It is not possible to understand the algesic 
behavior in this small group. Possible causes include the 
presence of unpredictable and varying pain in these patients 
with spontaneous worsening of symptoms irrespective of 
treatment, or the presence of mood-related disorders with 
a poor or erratic response to any medication.
In group 3, NPRS was reduced by 42.6% from baseline 
at week 4 after treatment (30% and 50% responder rates were 
60.7% and 42.9%, respectively, Table 3). In group 4, reduc-
tion in NPRS from baseline was 61.7% at week 4 after treat-
ment (30% and 50% responder rate were 83.9% and 64.5%, 
respectively, Table 4). The response to capsaicin 8% patch 
treatment was further maintained or even increased from week 
5 to at least week 12 in this subgroup, indicating long-lasting 
pain relief from a single patch application. Only in group 3 a 
response–offset rate constant could be estimated with a half-life 
of 7.8 weeks. This indicates that in group 3 the NPRS increased 
slowly (≈50% increase every 7.8 weeks from week 4 on), sug-
gesting that patients in group 3 would need retreatment after 
10 to 12 weeks (at that time the reduction in NPRS is less than 
20%). Furthermore, a design in which retreatment is applied 
would enable assessment of stable treatment reactions.
Table 2 Pharmacodynamic parameter estimates
Subgroup Typical estimate ± SE
1 2 3 4
Fixed effect parameters (θ)
NPRS0 6.0 ± 0.1 6.0 ± 0.2 6.0 ± 0.2 6.0 ± 0.2
konset (week–1) 0.76 ± 0.12 0 ± NE 0.76 ± 0.12 0.76 ± 0.12
koffset (week–1) 0 ± NE 0 ± NE 0.09 ± 0.04 0 ± NE
α −0.2 ± 0.08 0 ± NE 0.79 ± 0.06 0.79 ± 0.06
Interindividual random effect parameters
NPRS0 (%CV) 2.04 ± 0.323 (24%)
0.20 ± 0.08 (58%)
1.30 ± 0.75 (114%)
0.20 ± 0.08 (subgroup 1: 232%; 2–4: 57%)
konset (%CV)
koffset (%CV)
α (%CV)
Residual random effect parameter
Additive  
residual error
0.51 ± 0.082
Abbreviations: NPRS0, numerical pain rating score at baseline; konset, the response-
onset rate constant; koffset, the response-offset rate constant; SE, standard error; 
α, magnitude of effect.
Table 3 Percentage reduction in numerical pain rating score from baseline at week 4 and 12
Percentage of  
total population
Week 4  
% (mean ± SE)
Week 12  
% (mean ± SE)
Total population 100   33.7 ± 3.99   30.5 ± 4.84
Subgroups
Worsening of response (group 1) 3.3 −34.7 ± 10.3 −28.0 ± 1.84
No response (group 2) 30.8   0.01 ± 2.12 −5.62 ± 3.7
Maximum response with trend to return 
to baseline (group 3)
31.9   42.5 ± 5.94   15.6 ± 6.30
Maximum response which is maintained  
during 12 weeks (group 4)
34.1   61.7 ± 5.24   69.7 ± 5.11
Abbreviation: SE, standard error.
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We previously assessed the effect of a 1-week ketamine 
intravenous treatment on neuropathic pain in patients with 
complex regional pain syndrome type 1 (CRPS1).17,18 At the 
end of the 12-week follow-up, about 20% of the subjects 
had significant pain relief (ie, relief .30% of baseline pain 
score versus 47% in the current study, Table 4). While this 
suggests a rather poor efficacy of ketamine in the treatment 
of CRPS1 pain a subsequent subgroup analysis using a phar-
macodynamic mixture model showed that 37% (11/30) of 
patients were unresponsive to ketamine treatment following 
the treatment week (cf, our groups 1 and 2), 56% (17/30) of 
patients had an initial analgesic response (.50% of baseline 
pain) that slowly returned towards baseline levels (cf, our 
current group 3) and just 7% (2/30) patients had persis-
tent pain relief (cf, group 4).7 Evidently, patients that were 
unresponsive to ketamine are not suitable for retreatment. 
In contrast, patients in the ketamine group 3 were given the 
opportunity for retreatment with ketamine. Similarly, in our 
current study, patients in group 3 would be well served by 
retreatment.
The current and previous analyses indicate that subdivid-
ing patients into specific subgroups provides additional infor-
mation of the effect of pharmacological treatment on pain 
responses over time by identifying homogenous subgroups 
with two classes of responders (ie, group 3 and 4 responders). 
This approach is superior to the dichotomous classification 
of patients into responders versus nonresponders made at a 
specific time-point following treatment (eg, at an arbitrary 
week following treatment). Also in our study, conclusions 
drawn form a dichotomous study outcome at week 12 would 
significantly differ from those obtained using the current 
approach and would have missed the earlier but transient 
robust analgesic effects and would have suggested the need 
for retreatment at week 12 in most patients. Retreatment 
of patients in subgroups 1 and 2 is not warranted, as dis-
comfort will predominate without any therapeutic benefit. 
Retreatment in subgroup 4 is not needed since the analgesic 
response to the patch application was maintained during the 
observation period.
We restricted the mathematical modeling of the treat-
ment responses to analgesia. We did not take side effects 
into account, as serious adverse events did not occur 
(side effects were transient capsaicin-application related, 
and included local erythema, pain, and itching).13 Still, 
for other types of systemic medication that show similar 
large variability in response efficacy (eg, NMDA recep-
tor antagonists, GABAergic, antiepileptic and antide-
pressant medications) nontransient central side effects 
(sedation/nausea/dysphoria/hallucinations) may occur in 
patients that experience analgesia as well as those that do 
not.17,18 Especially for these medications with a narrow thera-
peutic index the characterization of subgroups is important as 
it allows a more accurate description of the efficacy–safety 
balance. Concomitant modeling of analgesia and side effects 
will allow the development of so-called utility functions in 
which the balance between safety and efficacy is quantified 
over time.19,20 For example patients that do not respond to 
medication (cf, our groups 1 and 2) are especially vulnerable 
to a potential imbalance between efficacy and safety as they 
lack any treatment advantage.
A limitation to our analysis is that in case of small 
response groups (subgroup 1 with just three patients), 
changes observed in effect could easily be due to random 
variation without any relationship to treatment. Furthermore, 
while our classification into four response groups is an impor-
tant enrichment tool (eg, for assessment of treatment efficacy 
or an indicator for the need for treatment switch) it remains 
a post-hoc analysis. A useful addition to our analysis would 
be to incorporate a priori functional or neurosensory testing 
allowing response prediction. To the best of our knowledge, 
so far, no useful link has been made between any functional 
testing and drug response outcome. A first approach could 
be the use of quantitative sensory testing (QST) or brain-
evoked potentials using electrical (SEP) or laser stimulation 
(LEP) of the skin prior to treatment. For example, specific 
QST, SEP, or LEP patterns detected may be linked to specific 
response groups. Our model-based approach can be seen as a 
complementary tool to functional tests like QST, combining 
mechanistic insights in chronic pain conditions with patient 
outcome measures. An additional approach could be to link 
response groups to patient covariates (including patient 
characteristics, genetic factors (eg, variations in the TRPV1 
gene), disease severity/state. While this initially requires 
post-hoc testing, subsequent studies may be designed to 
address the prognostic value of these covariates in predicting 
the response to treatment. The developed pharmacodynamic 
model can be used as a basis for identification of covariates 
that have potential prognostic value for prediction of treat-
ment outcome, our patient population, however, was too small 
to allow for such covariate analysis.
In conclusion, we showed that characterization of the 
time course of the analgesic response is essential to further 
understand the heterogeneity in treatment effect (and study 
  population). In the current study in a relatively small popu-
lation of neuropathic pain patients, about two-thirds of the 
patients showed significant reduction in pain   following a 
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  single application of capsaicin 8% patch. In one subpopulation 
(34%) the 30% and 50% responder rate was around 90% and 
70% at week 12. These results indicate that the single topical 
application of capsaicin 8% patch provides an effective and 
long-lasting treatment in DPN pain, although the efficacy 
should be viewed in light of the open-label study design. 
Finally, we and others,17,18 have shown that the model-based 
approach may have added value in analyzing longitudinal 
data from chronic pain trials and may provide insights into 
the nature of drug response and allows the optimization of 
treatment algorithms for patients suffering from chronic pain 
conditions. We applied the mixture model analysis to a small 
population of DPN patients treated with a single capsaicin 
8% patch, but it may be a valuable tool for all therapies with 
similar large response variability in a variety of chronic pain 
syndromes, including ketamine, pregabalin, duloxetine, and 
gabapentin.17,21–23
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